Menu Back toSession-0602-Managing-Post-Approval-CMC-Changes-in-China-and-the-US-II

The 7th DIA China Annual Meeting


Session 0602 Managing Post-Approval CMC Changes in China and the US - II

Session Chair(s)

Melly  Lin

Melly Lin

  • Senior Regulatory Manager, CMC Policy,
  • Roche(China) Holding Ltd, China
Chi-Wan  Chen, PhD

Chi-Wan Chen, PhD

  • Executive Director, Global CMC
  • Pfizer Inc, United States

Experience Sharing on Multiple Sites for Biologics in Taiwan

Speaker(s)

Jofeng  Chi

Experience Sharing on Multiple Sites for Biologics in Taiwan

Jofeng Chi

  • Section Chief, Taiwan
  • Food and Drug Administration Ministry of Health and Welfare, China
Chi-Wan  Chen, PhD

Managing post-approval changes for chemical drugs-case studies (EN&CN)

Chi-Wan Chen, PhD

  • Executive Director, Global CMC
  • Pfizer Inc, United States
Andrew  Chang, PhD

Managing Post-Approval CMC Changes for Biologics in a Global Market – Case Studies (EN&CN)

Andrew Chang, PhD

  • Vice President, Quality and Regulatory Compliance, QI&I, Corporate Quality
  • Novo Nordisk A/S, United States

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU: jxu@kellencompany.com, or Sofie Peeters: speeters@kellencompany.com
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
dia@diachina.org
Tel: +86 10 5704 2650